Marine Bioactive Peptides: Health from the Ocean
Marine Bioactive Peptides
700+ identified
Over 700 bioactive peptides have been isolated from marine organisms, spanning antioxidant, antimicrobial, antihypertensive, and anticancer activities.
Shahidi et al., Marine Drugs, 2025
Shahidi et al., Marine Drugs, 2025
View as imageThe ocean covers 71% of Earth's surface and contains an estimated 2.2 million eukaryotic species, most of them undescribed. Marine organisms have evolved in environments of extreme pressure, temperature, salinity, and microbial competition, producing defense and signaling molecules that have no terrestrial counterpart. Among these molecules, bioactive peptides have emerged as one of the most promising classes of marine-derived compounds for human health applications.
Marine bioactive peptides are short protein fragments, typically 2-30 amino acids long, isolated from fish, shellfish, algae, sponges, tunicates, and other ocean organisms. They demonstrate a range of biological activities: antioxidant, antimicrobial, antihypertensive, anti-inflammatory, anticancer, and immunomodulatory.[1] Unlike many synthetic drugs, these peptides are derived from food-grade or naturally occurring proteins, raising the possibility of nutraceutical applications alongside pharmaceutical development.
This pillar article covers the major sources of marine bioactive peptides, their mechanisms of action across disease categories, the extraction and identification methods that have made this field possible, and the critical gap between laboratory findings and clinical application. For specific marine sources, see the detailed articles on algae-derived peptides and fish collagen peptides.
Key Takeaways
- Over 700 bioactive peptides have been identified from marine sources, with activities spanning antioxidant, antimicrobial, antihypertensive, and anticancer domains (Shahidi et al., 2025)
- Fish processing byproducts (skin, bones, viscera) are the largest source of marine bioactive peptides, turning waste streams into potential health products
- ACE-inhibitory peptides from fish protein hydrolysates are the most clinically advanced marine peptides, with some showing blood pressure reduction in human studies
- Marine antimicrobial peptides show activity against drug-resistant bacteria, offering potential alternatives to conventional antibiotics (Gao et al., 2025)
- Marine collagen peptides from fish skin have entered commercial markets as supplements, though clinical evidence varies by endpoint
- The translation from marine peptide discovery to approved therapeutics remains slow, with most compounds still in preclinical stages
Where Marine Bioactive Peptides Come From
Marine bioactive peptides are not extracted as pre-formed molecules. They exist encrypted within larger parent proteins and must be released through enzymatic hydrolysis, microbial fermentation, or chemical processing. The peptide's bioactivity depends on its specific amino acid sequence, which is determined by both the parent protein and the enzyme used to cleave it.
Fish and shellfish
Fish are the most extensively studied marine source of bioactive peptides. Virtually every commercially important species has been investigated: salmon, tuna, cod, sardine, mackerel, tilapia, and dozens of others. Critically, much of this research focuses on processing byproducts, the skin, bones, scales, viscera, and trimmings that constitute 30-70% of fish mass and are typically discarded or rendered into low-value fishmeal.
Rengasamy and colleagues reviewed the breadth of bioactive peptides from marine sources in 2019, documenting peptides with ACE-inhibitory, antioxidant, antimicrobial, and anticancer activities across dozens of marine species.[2] Fish collagen, particularly from skin and scales, is a rich source of hydroxyproline-containing peptides that differ structurally from mammalian collagen peptides. For a focused analysis, see fish collagen peptides and their health effects.
Salvatore and colleagues reviewed marine collagen sources in 2020, noting that fish-derived collagen peptides offer advantages over bovine or porcine sources for consumers with religious dietary restrictions or concerns about transmissible spongiform encephalopathies.[3]
Seaweed and microalgae
Algae represent an underexplored but increasingly important source of marine bioactive peptides. Wang and colleagues reviewed seaweed-derived proteins and peptides in 2025, documenting antioxidant, anti-inflammatory, and ACE-inhibitory activities from brown, red, and green algae species.[4]
Microalgae like Spirulina and Chlorella contain up to 70% protein by dry weight, making them concentrated sources of potential bioactive peptides. Enzymatic hydrolysis of microalgal protein yields peptide fractions with antioxidant and antihypertensive activities. The scalability of microalgal cultivation, independent of arable land and fresh water, makes these organisms particularly attractive for sustainable peptide production. For deeper coverage, see algae-derived peptides as functional food.
Marine invertebrates
Sponges, tunicates, sea cucumbers, and jellyfish have produced some of the most structurally novel marine peptides. Marine sponges in particular have yielded cyclic peptides and depsipeptides with potent anticancer and antimicrobial activities, several of which have entered clinical trials as drug candidates (though as synthetic analogues rather than directly extracted compounds).
Jellyfish collagen, reviewed by Pesterau and colleagues in 2025, represents an emerging source of marine collagen peptides from an organism that is increasing in abundance due to ocean warming and overfishing of predators.[5] Jellyfish are approximately 95% water but their remaining dry mass contains substantial collagen, which can be hydrolyzed into bioactive peptide fragments with antioxidant and antihypertensive activities. Given that jellyfish blooms now cause economic damage to fisheries, power plants, and tourism worldwide, converting this biomass into health products represents an elegant intersection of environmental management and biotechnology.
Biological Activities: What Marine Peptides Do
Antihypertensive (ACE-inhibitory) peptides
The most clinically advanced application of marine bioactive peptides is blood pressure reduction through inhibition of angiotensin-converting enzyme (ACE). ACE converts angiotensin I to angiotensin II, a potent vasoconstrictor; blocking this enzyme is the mechanism behind the entire class of ACE-inhibitor drugs (lisinopril, enalapril, ramipril).
Walquist and colleagues reviewed marine-derived peptides with antihypertensive properties in 2024, documenting dozens of ACE-inhibitory peptide sequences isolated from fish, shellfish, and algae protein hydrolysates.[6] Several fish-derived ACE-inhibitory peptides have progressed to human studies, with modest but measurable reductions in systolic blood pressure reported in randomized controlled trials.
The peptide sequences responsible for ACE inhibition tend to be short (2-12 amino acids), hydrophobic at the C-terminus, and often contain proline or hydroxyproline. Fish collagen hydrolysates are particularly rich in these sequences due to the high proline/hydroxyproline content of collagen.
An important distinction: marine ACE-inhibitory peptides are substantially less potent than pharmaceutical ACE inhibitors on a molar basis. Captopril, the first ACE inhibitor drug, has an IC50 in the low nanomolar range; most marine ACE-inhibitory peptides have IC50 values in the micromolar range, making them 100-1000 times less potent. Their potential value lies in food-based prevention rather than drug-level treatment. A fish protein hydrolysate will not replace lisinopril for a patient with established hypertension, but it might contribute to blood pressure management in borderline or pre-hypertensive individuals as part of a dietary approach.
Several commercial products based on fish-derived ACE-inhibitory peptides have been marketed in Japan and Europe, including sardine peptide preparations (Valtyron) and bonito peptide products. These have received regulatory recognition in some jurisdictions as foods with health claims, though the clinical evidence supporting their blood pressure effects is limited to small trials with modest effect sizes (typically 3-5 mmHg systolic reduction).
Antioxidant peptides
Marine organisms living in oxygen-rich surface waters or near hydrothermal vents have evolved robust oxidative stress defense systems. Peptides released from these organisms' proteins often retain antioxidant activity through several mechanisms:
- Direct radical scavenging (particularly peptides containing aromatic amino acids or histidine)
- Metal ion chelation (preventing Fenton-type radical generation)
- Inhibition of lipid peroxidation
- Enhancement of endogenous antioxidant enzyme activity
Shahidi and colleagues provided a comprehensive review of marine-derived peptide bioactivities in 2025, confirming that antioxidant peptides from fish, shrimp, and algae consistently demonstrate in vitro radical scavenging activity.[7] The challenge, as with all antioxidant peptides from food sources, is translating in vitro antioxidant capacity to in vivo health outcomes. The correlation between a peptide's DPPH radical scavenging activity in a test tube and its ability to reduce oxidative damage in a living organism is weak.
Antimicrobial peptides
Marine antimicrobial peptides (AMPs) represent one of the most clinically urgent applications of marine peptide research. With antibiotic resistance rising globally, novel antimicrobial compounds from marine sources could address an unmet medical need.
Gao and colleagues reviewed advances in marine AMPs in 2025, documenting peptides from fish, shrimp, crabs, mollusks, and marine microorganisms with activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains.[8] Beyer and colleagues in 2026 demonstrated that marine-inspired antimicrobial peptides can disrupt bacterial membranes through mechanisms distinct from conventional antibiotics, potentially reducing the likelihood of resistance development.[9]
For a focused analysis of marine AMPs as drug candidates, see marine antimicrobial peptides: the ocean's untapped pharmacy. The broader question of whether antimicrobial peptides can solve antibiotic resistance remains open but is one of the most active areas in peptide therapeutics.
Selvaraj and colleagues reviewed the current state of marine-derived AMPs in 2026, emphasizing both their structural diversity and the technical challenges of developing them into clinical antibiotics.[10]
Anticancer peptides
Marine organisms have yielded several peptide-based anticancer compounds that have reached clinical trials. Kahalalide F (from a sea slug), dolastatin 10 (from a sea hare), and aplidine (from a tunicate) are marine-derived peptides or peptide analogues that have been tested in human cancer trials. Several antibody-drug conjugates currently approved for cancer treatment use marine-derived peptide payloads.
Yao and colleagues reviewed marine peptides as potential anticancer agents in 2024, documenting mechanisms including cell cycle arrest, apoptosis induction, anti-angiogenesis, and immunomodulation.[11] The structural novelty of marine peptides, including cyclic structures, unusual amino acids (like D-amino acids and beta-amino acids), N-methylated backbones, and depsipeptide bonds (where an ester replaces an amide), creates pharmacological diversity not found in terrestrial peptide libraries.
The most clinically successful marine-derived peptide compounds are antibody-drug conjugate (ADC) payloads. Brentuximab vedotin (Adcetris) uses a synthetic analogue of dolastatin 10, originally isolated from the sea hare Dolabella auricularia. Enfortumab vedotin (Padcev) uses the same payload chemistry. These drugs generate billions of dollars in annual revenue, demonstrating that marine peptide chemistry can yield transformative therapeutics when properly developed. The parent peptides, however, were too toxic for direct use as drugs; conjugation to antibodies that target them specifically to cancer cells was necessary to achieve an acceptable safety profile.
Anti-inflammatory and immunomodulatory peptides
Guryanova and colleagues reviewed multifaceted marine peptide activities in 2025, highlighting anti-inflammatory peptides from fish, algae, and marine invertebrates that modulate NF-kB, MAPK, and other inflammatory signaling pathways.[12] Marine peptides have shown ability to reduce TNF-alpha, IL-6, and IL-1-beta production in cell culture, and some have demonstrated protective effects in animal models of inflammatory bowel disease, arthritis, and neuroinflammation.
How Marine Bioactive Peptides Are Extracted and Identified
The discovery pipeline for marine bioactive peptides has evolved substantially over the past decade:
Enzymatic hydrolysis
This remains the primary method for releasing bioactive peptides from marine proteins. Common enzymes include pepsin, trypsin, alcalase, papain, and flavourzyme. The choice of enzyme determines which peptide bonds are cleaved and therefore which peptide sequences are released. The same fish protein can yield different bioactive peptide profiles depending on the enzyme, hydrolysis time, temperature, and pH.
Novel pretreatment technologies
Ultrasound-assisted extraction, microwave-assisted extraction, high hydrostatic pressure processing, and pulsed electric fields have been applied to improve peptide yield and modify bioactivity profiles. These physical treatments can unfold proteins and expose cleavage sites that are inaccessible under standard conditions.
Each pretreatment alters the peptide profile differently. Ultrasound creates cavitation bubbles that physically disrupt protein structure, increasing enzyme accessibility by up to 40% in some studies. High hydrostatic pressure (100-600 MPa) denatures proteins without heat, preserving heat-sensitive bioactive sequences that would be destroyed by thermal processing. Pulsed electric fields create transient pores in cell membranes, improving extraction of intracellular proteins from marine organisms before enzymatic hydrolysis. The combination of physical pretreatment and optimized enzymatic hydrolysis can produce peptide profiles with significantly different bioactivity profiles than either approach alone, adding a layer of complexity but also control to the production process.
Bioinformatics and in silico approaches
Computational screening of marine protein databases for encrypted bioactive sequences has accelerated peptide discovery. Machine learning models trained on known bioactive sequences can predict peptide activity from primary structure alone, reducing the need for exhaustive wet-lab screening. This approach is particularly valuable for marine organisms where protein material is scarce or difficult to obtain.
The bioinformatics approach works in both directions: forward screening (predicting which peptide sequences within a marine protein are likely to be bioactive) and inverse design (starting with a desired activity profile and designing peptide sequences to match). Databases like BIOPEP-UWM and the Marine Peptide Database catalog thousands of marine-derived bioactive sequences, enabling virtual screening campaigns that can identify promising candidates before any laboratory work begins.
However, computational prediction accuracy remains limited. The relationship between peptide sequence and bioactivity is complex, influenced by three-dimensional structure, environmental conditions, and interactions with biological targets that are difficult to model computationally. In silico predictions require experimental validation, and the false positive rate for predicted activities is high. These tools accelerate discovery but do not replace wet-lab confirmation.
Marine collagen as a commercial case study
Fish collagen peptides represent the most commercially mature marine bioactive peptide category. Rahabi and colleagues reviewed bioactive fish collagen peptides in 2022, documenting their effects on skin hydration, joint health, and wound healing.[13] Several fish collagen peptide products are commercially available as dietary supplements, and the global marine collagen market continues to grow. Whether these products deliver clinically meaningful outcomes depends on the specific peptide composition, dose, and measured endpoint. Skin hydration studies generally show more consistent positive results than joint health studies, possibly because the skin is a more accessible target for orally absorbed collagen peptides. For the broader clinical picture on collagen peptides and joint health, the evidence is stronger for some endpoints than others.
The Translation Gap: From Ocean to Medicine
Despite the breadth of marine bioactive peptide research, the translation from discovery to clinical application remains slow. Several factors explain this gap:
Bioavailability: Most marine bioactive peptides are tested in vitro or via injection in animals. Oral bioavailability, the relevant route for both nutraceutical and most pharmaceutical applications, remains poorly characterized for most marine peptides. Gastrointestinal degradation, first-pass metabolism, and poor membrane permeability all limit how much active peptide reaches systemic circulation.
Standardization: Marine peptide hydrolysates are complex mixtures. Batch-to-batch variability in enzyme activity, protein source quality, and processing conditions creates products with inconsistent peptide profiles. For clinical trials and regulatory approval, standardized, reproducible products are essential.
Scale: While fish processing byproducts are abundant, extracting specific bioactive peptide sequences at pharmaceutical purity and scale is expensive. Fermentation-based production of specific peptide sequences, or chemical synthesis, may be necessary for drug development.
Regulatory pathway: Marine bioactive peptides occupy an ambiguous regulatory space between food/dietary supplements and pharmaceutical drugs. The regulatory requirements differ dramatically between these categories, and most marine peptide products are marketed as supplements under structure/function claims rather than pursuing drug approval.
Clinical evidence quality: Most human studies of marine bioactive peptides are small, short-term, and conducted by researchers affiliated with the companies marketing the products. Large, independent, placebo-controlled trials with hard clinical endpoints (cardiovascular events, cancer incidence, infection rates) are almost entirely absent.
Species identification and sourcing: The bioactive peptide profile of a "fish collagen hydrolysate" depends heavily on the fish species, tissue type (skin vs. bone vs. scale), enzyme used, and processing parameters. Two products both labeled "marine collagen peptides" may contain entirely different peptide sequences with different biological activities. Consumer products rarely specify these details, making it impossible for consumers (or researchers) to replicate or compare results across products.
Environmental contaminant risk: Marine organisms accumulate environmental contaminants including heavy metals (mercury, cadmium, lead), persistent organic pollutants, and microplastics. Peptide extraction processes may concentrate or remove these contaminants depending on the methodology. Quality-controlled manufacturing must include contaminant testing, but supplement industry oversight varies widely by jurisdiction.
The Sustainability Dimension
Marine bioactive peptide research intersects with ocean sustainability in two ways. First, using fish processing byproducts for peptide extraction converts a waste stream into a value-added product, improving the economics and environmental footprint of the fishing industry. Second, overfishing and ocean acidification threaten the very marine ecosystems that produce these compounds, creating urgency around both sustainable harvesting and alternative production methods (aquaculture, cell culture, recombinant expression).
The tension between exploitation and conservation is particularly acute for marine invertebrates like sponges and tunicates, which produce the most pharmacologically novel peptides but are difficult to cultivate at scale. Wild harvest of sponges for drug production is ecologically destructive and fails to provide reliable supply. Supply-chain solutions, including total chemical synthesis, heterologous expression in bacteria or yeast, and aquaculture of marine invertebrates, are being developed to decouple drug production from wild harvest.
The sustainability argument is strongest for fish-derived peptides: the global fishing industry produces approximately 20-30 million tons of byproduct annually. Converting even a fraction of this waste into bioactive peptide products would represent a significant value addition without requiring additional harvest. Algae-derived peptides are similarly sustainable because microalgal cultivation can be performed in photobioreactors on non-arable land using seawater or wastewater, producing high-protein biomass with minimal environmental footprint compared to terrestrial agriculture.
The Bottom Line
Marine bioactive peptides represent one of the most diverse natural peptide libraries available for human health applications, with over 700 identified sequences spanning antioxidant, antimicrobial, antihypertensive, anti-inflammatory, and anticancer activities. Fish processing byproducts and algae are the most scalable sources. ACE-inhibitory peptides for blood pressure management and marine collagen peptides for skin and joint health are the most commercially advanced applications. The fundamental challenge remains translation: converting in vitro activity from diverse marine sources into standardized, clinically validated products that demonstrably improve human health outcomes.